The Role of Managed Care Pharmacy in Improving Access to Naloxone: Findings from the AMCP Addiction Treatment Advisory Group
dc.contributor.author | AMCP Addiction Treatment Advisory Group | |
dc.contributor.author | Lenz, Kimberly J. | |
dc.date | 2022-08-11T08:08:06.000 | |
dc.date.accessioned | 2022-08-23T15:42:32Z | |
dc.date.available | 2022-08-23T15:42:32Z | |
dc.date.issued | 2016-12-20 | |
dc.date.submitted | 2017-01-13 | |
dc.identifier.citation | Academy of Managed Care Pharmacy. The Role of Managed Care Pharmacy in Improving Access to Naloxone: Findings from the AMCP Addiction Treatment Advisory Group. December 2016. http://bit.ly/2fJogY9 | |
dc.identifier.uri | http://hdl.handle.net/20.500.14038/26872 | |
dc.description.abstract | Kimberly Lenz, PharmD, a clinical pharmacy manager in the Office of Clinical Affairs, provided insight and expertise for this report as a member of the Academy of Managed Care Pharmacy's Addiction Treatment Advisory Group. The group's report identifies barriers to care and details how managed care organizations can better address the opioid addiction crisis, including improving access to naloxone and Medication Assisted Therapies (MAT) as well as ensuring benefit design will support alternative pain management methods. | |
dc.language.iso | en_US | |
dc.relation.url | http://bit.ly/2fJogY9 | |
dc.subject | Behavioral Health | |
dc.subject | Opioid Management | |
dc.subject | Pharmacy | |
dc.subject | Health Services Administration | |
dc.subject | Health Services Research | |
dc.subject | Pharmacy and Pharmaceutical Sciences | |
dc.subject | Substance Abuse and Addiction | |
dc.title | The Role of Managed Care Pharmacy in Improving Access to Naloxone: Findings from the AMCP Addiction Treatment Advisory Group | |
dc.type | Report | |
dc.identifier.legacycoverpage | https://escholarship.umassmed.edu/commed_pubs/11 | |
dc.identifier.contextkey | 9545464 | |
html.description.abstract | <p>Kimberly Lenz, PharmD, a clinical pharmacy manager in the Office of Clinical Affairs, provided insight and expertise for this report as a member of the Academy of Managed Care Pharmacy's Addiction Treatment Advisory Group. The group's report identifies barriers to care and details how managed care organizations can better address the opioid addiction crisis, including improving access to naloxone and Medication Assisted Therapies (MAT) as well as ensuring benefit design will support alternative pain management methods.</p> | |
dc.identifier.submissionpath | commed_pubs/11 | |
dc.contributor.department | Commonwealth Medicine, Office of Clinical Affairs | |
dc.contributor.department | Commonwealth Medicine, Center for Health Policy and Research |